• 1
    U.S. Cancer Statistics Working Group. United States cancer statistics: 2000 incidence. Atlanta: Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute, 2003.
  • 2
    Ries LG, Smith M, Gurney J, Linet M, Tmara T, Young JL. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. Bethesda: National Cancer Institute, 1999.
  • 3
    Schmid-Wendtner MH, Berking C, Baumert J, et al. Cutaneous melanoma in childhood and adolescence: an analysis of 36 patients. J Am Acad Dermatol. 2002; 46: 874879.
  • 4
    Gibbs P, Moore A, Robinson W, Walsh P, Golitz L, Gonzalez R. Pediatric melanoma: are recent advances in the management of adult melanoma relevant to the pediatric population. J Pediatr Hematol Oncol. 2000; 22: 428432.
  • 5
    Hamre MR, Chuba P, Bakhshi S, Thomas R, Severson RK. Cutaneous melanoma in childhood and adolescence. Pediatr Hematol Oncol. 2002; 19: 309317.
  • 6
    Gelbard SN, Tripp JM, Marghoob AA, et al. Management of Spitz nevi: a survey of dermatologists in the United States. J Am Acad Dermatol. 2002; 47: 224230.
  • 7
    Barnhill RL, Argenyi ZB, From L, et al. Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol. 1999; 30: 513520.
  • 8
    Saenz NC, Saenz-Badillos J, Busam K, LaQuaglia MP, Corbally M, Brady MS. Childhood melanoma survival. Cancer. 1999; 85: 750754.
  • 9
    Williams ML, Pennella R. Melanoma, melanocytic nevi, and other melanoma risk factors in children. J Pediatr. 1994; 124: 833845.
  • 10
    Pappo AS. Melanoma in children and adolescents. Eur J Cancer. 2003; 39: 26512661.
  • 11
    Pappo AS, Ries L, Herzog C, Bleyer A. Malignant melanoma in the first three decades of life: a report from the U.S. Surveillance, Epidemiology, and End Results (SEER) Program. Proc Am Soc Clin Oncol. 2004; 22: 724S.
  • 12
    Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (Stage II). Ann Surg. 1981; 193: 377388.
  • 13
    Balch CM, Murad TM, Soong SJ, Ingalls AL, Halpern NB, Maddox WA. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg. 1978; 188: 732742.
  • 14
    Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001; 19: 36223634.
  • 15
    Milton GW, Shaw HM, Thompson JF, McCarthy WH. Cutaneous melanoma in childhood: incidence and prognosis. Australas J Dermatol. 1997; 38( Suppl 1): S44S48.
  • 16
    Rao BN, Hayes FA, Pratt CB, et al. Malignant melanoma in children: its management and prognosis. J Pediatr Surg. 1990; 25: 198203.
  • 17
    Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996; 14: 717.
  • 18
    Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004; 10: 16701677.
  • 19
    Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected Stage IIB–III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001; 19: 23702380.
  • 20
    Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000; 18: 24442458.
  • 21
    Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ. Malignant melanoma of the skin (excluding eyelid). In: BeahrsOH, HensonDE, HutterRVP, KennedyBJ, eds. AJCC manual for staging of cancer, 4th ed. Philadelphia: JB Lippincott Company, 1992: 143145.
  • 22
    Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol. 2002; 20: 18181825.
  • 23
    Sabel MS, Sondak VK. Pros and cons of adjuvant interferon in the treatment of melanoma. Oncologist. 2003; 8: 451458.
  • 24
    Spatz A, Ruiter D, Hardmeier T, et al. Melanoma in childhood: an EORTC-MCG multicenter study on the clinico-pathological aspects. Int J Cancer. 1996; 68: 317324.
  • 25
    Lohmann CM, Coit DG, Brady MS, Berwick M, Busam KJ. Sentinel lymph node biopsy in patients with diagnostically controversial spitzoid melanocytic tumors. Am J Surg Pathol. 2002; 26: 4755.
  • 26
    Su LD, Fullen DR, Sondak VK, Johnson TM, Lowe L. Sentinel lymph node biopsy for patients with problematic spitzoid melanocytic lesions: a report on 18 patients. Cancer. 2003; 97: 499507.
  • 27
    Smith KJ, Barrett TL, Skelton HG 3rd, Lupton GP, Graham JH. Spindle cell and epithelioid cell nevi with atypia and metastasis (malignant Spitz nevus). Am J Surg Pathol. 1989; 13: 931939.
  • 28
    Mehregan AH, Mehregan DA. Malignant melanoma in childhood. Cancer. 1993; 71: 40964103.
  • 29
    Tate PS, Ronan SG, Feucht KA, Eng AM, Das Gupta TK. Melanoma in childhood and adolescence: clinical and pathological features of 48 cases. J Pediatr Surg. 1993; 28: 2172122.
  • 30
    Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19: 36353648.
  • 31
    Kogut KA, Fleming M, Pappo AS, Schropp KP. Sentinel lymph node biopsy for melanoma in young children. J Pediatr Surg. 2000; 35: 965966.
  • 32
    Zuckerman R, Maier JP, Guiney WB Jr., Huntsman WT, Mooney EK. Pediatric melanoma: confirming the diagnosis with sentinel node biopsy. Ann Plast Surg. 2001; 46: 394399.
  • 33
    Toro J, Ranieri JM, Havlik RJ, Coleman JJ 3rd, Wagner JD. Sentinel lymph node biopsy in children and adolescents with malignant melanoma. J Pediatr Surg. 2003; 38: 10631065.